Spero Therapeutics (SPRO)

Company Profile

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Company profile

Ticker

SPRO

Exchange

NASDAQ

Website

sperotherapeutics.com

CEO

Ankit Mahadevia

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

Spero Therapeutics, LLC

SEC CIK

0001701108

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

New Pharma License Holdings • Spero Cantab, Inc. • Spero Cantab UK Limited • Spero Europe, Ltd. • Spero Legacy STI, Inc. • Spero Potentiator, Inc. • Spero Potentiator PTY LTD • Spero Securities Corporation ...

SPRO stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

1 Feb 23

CT ORDER

Confidential treatment order

19 Jan 23

8-K

Results of Operations and Financial Condition

9 Jan 23

$9.00 mm in equity, sold $9.00 mm, 1 investor

14 Nov 22

S-8

Registration of securities for employees

14 Nov 22

8-K

Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

14 Nov 22

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

8 Nov 22

8-K

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

22 Sep 22

8-K

Departure of Directors or Certain Officers

19 Sep 22

Transcripts

View all

SPRO

Earnings call transcript

2022 Q3

15 Nov 22

SPRO

Earnings call transcript

2022 Q2

11 Aug 22

SPRO

Earnings call transcript

2022 Q1

17 May 22

SPRO

Earnings call transcript

2021 Q4

1 Apr 22

SPRO

Earnings call transcript

2021 Q3

11 Nov 21

SPRO

Earnings call transcript

2021 Q2

7 Aug 21

SPRO

Earnings call transcript

2021 Q1

9 May 21

SPRO

Earnings call transcript

2020 Q4

12 Mar 21

SPRO

Earnings call transcript

2020 Q3

7 Nov 20

SPRO

Earnings call transcript

2020 Q2

8 Aug 20

Latest ownership filings

View all

Initial statement of insider ownership

Financial summary

Financial statements Chart SPRO financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	50.45 mm	50.45 mm	50.45 mm	50.45 mm	50.45 mm	50.45 mm
Cash burn (monthly)	(no burn)	5.20 mm	3.94 mm	7.97 mm	319.00 k	6.63 mm
Cash used (since last report)	n/a	21.97 mm	16.66 mm	33.66 mm	1.35 mm	28.01 mm
Cash remaining	n/a	28.48 mm	33.78 mm	16.79 mm	49.10 mm	22.44 mm
Runway (months of cash)	n/a	5.5	8.6	2.1	153.9	3.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

SPRO institutional ownership history Ownership history

84.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	69	82	-15.9%
Opened positions	13	16	-18.8%
Closed positions	26	35	-25.7%
Increased positions	11	20	-45.0%
Reduced positions	18	22	-18.2%

13F shares	Current	Prev Q	Change
Total value	185.49 mm	152.93 mm	+21.3%
Total shares	29.67 mm	30.88 mm	-3.9%
Total puts	326.20 k	36.60 k	+791.3%
Total calls	27.80 k	40.80 k	-31.9%
Total put/call ratio	11.7	0.9	+1208.0%

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	3.41 mm	$0.00	0.0%
Aquilo Capital Management	3.40 mm	$6.81 mm	-36.0%
PFE Pfizer	2.36 mm	$32.98 mm	0.0%
AWM Investment	2.30 mm	$4.60 mm	NEW
BVF	1.93 mm	$3.86 mm	-37.6%
GSK GSK	1.74 mm	$24.68 mm	0.0%
Anson Funds Management	1.47 mm	$2.95 mm	NEW
Atlas Venture Associates IX	1.38 mm	$2.75 mm	0.0%
Atlas Venture Fund IX	1.38 mm	$22.05 mm	0.0%
Vanguard	1.05 mm	$2.11 mm	-15.4%

Largest transactions	Shares	Bought/sold	Change
AWM Investment	2.30 mm	+2.30 mm	NEW
Aquilo Capital Management	3.40 mm	-1.92 mm	-36.0%
Anson Funds Management	1.47 mm	+1.47 mm	NEW
BVF	1.93 mm	-1.16 mm	-37.6%
Murchinson	762.70 k	+762.70 k	NEW
Renaissance Technologies	214.70 k	-724.32 k	-77.1%
D. E. Shaw & Co.	0.00	-649.33 k	EXIT
Two Sigma Investments	0.00	-437.28 k	EXIT
Millennium Management	688.40 k	+373.75 k	+118.8%
Dimensional Fund Advisors	10.00 k	-274.95 k	-96.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SPRO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Feb 23	Sath Shukla	Common Stock	Sell	Dispose S	No	Yes	1.8279	9,504	17.37 k	312,517
2 Feb 23	Joseph Tamara L	Common Stock	Sell	Dispose S	No	No	1.86	3,394	6.31 k	324,644
2 Feb 23	Timothy Keutzer	Common Stock	Sell	Dispose S	No	No	1.86	3,394	6.31 k	327,144
1 Feb 23	Mahadevia Ankit	Common Stock	Grant	Acquire A	No	No	0	531,914	0.00	810,118
1 Feb 23	Kamal Hamed	Common Stock	Grant	Acquire A	No	No	0	265,957	0.00	475,957
1 Feb 23	Sath Shukla	Common Stock	Grant	Acquire A	No	No	0	265,957	0.00	322,021
1 Feb 23	Joseph Tamara L	Common Stock	Grant	Acquire A	No	No	0	265,957	0.00	328,038
1 Feb 23	Timothy Keutzer	Common Stock	Grant	Acquire A	No	No	0	265,957	0.00	330,538